Treatment of Panc-1 cells with PBS, 0.5 μM Neuropathiazol, 2 μM Neuropathiazol, 1 μM gemcitabine, 5 μM cisplatin, or 5 μM paclitaxel for 48 h and subsequent measurement of relative luciferase activity to assess NeuroD1 promoter activity showed that the first-line chemotherapeutic drugs commonly used to treat pancreatic cancer did not affect NeuroD1 promoter activity in Panc-1 cells. This evidence concerns the gene NEUROD1 and familial pancreatic carcinoma.